Cargando…
In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus
The coronavirus disease, COVID-19, caused by the novel coronavirus SARS-CoV-2, which first emerged in Wuhan, China and was made known to the World in December 2019 turned into a pandemic causing more than 126,124 deaths worldwide up to April 16th, 2020. It has 79.5% sequence identity with SARS-CoV-1...
Autores principales: | Eleftheriou, Phaedra, Amanatidou, Dionysia, Petrou, Anthi, Geronikaki, Athina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321236/ https://www.ncbi.nlm.nih.gov/pubmed/32485894 http://dx.doi.org/10.3390/molecules25112529 |
Ejemplares similares
-
Thiazole/Thiadiazole/Benzothiazole Based Thiazolidin-4-One Derivatives as Potential Inhibitors of Main Protease of SARS-CoV-2
por: Petrou, Anthi, et al.
Publicado: (2022) -
Novel Thiazolidin-4-ones as Potential Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
por: Petrou, Anthi, et al.
Publicado: (2019) -
In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021) -
Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2
por: Tripathi, Praveen Kumar, et al.
Publicado: (2020) -
In silico assessment of diterpenes as potential inhibitors of SARS-COV-2 main protease
por: Abdelrady, Yousef A, et al.
Publicado: (2023)